Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Effectiveness of a Guided, Web-based, Stepped-care-approach to Cognitive Behavioral Therapy for Insomnia in Cancer Survivors

NCT07876661 · tracked via the Priya Life Science Belgium tracker
Phase
Not applicable
Started
2026-10-15
Last updated
2026-10-15

Condition(s) studied

NeoplasmsCancer SurvivorshipInsomnia

Investigational drug(s) / intervention(s)

Stepped-care Cognitive Behavioral Therapy for InsomniaStandard web-based Cognitive Behavioral Therapy for InsomniaControl arm - Care as usual with sleep hygiene leaflet

Stepped-care Cognitive Behavioral Therapy for Insomnia: Step 1: Participants receive access to an online self-guided CBT-I module containing educational videos, psychoeducation, and behavioural exercises and 1 online face-to-face sleep coaching session delivered by a trained healthcare provider. The intervention includes sleep education and sleep hygiene, stimulus control, and individualized behavioural advice to improve sleep. Step 2: Participants who do not achieve remission after Step 1 proceed to Step 2, consisting of the eSTANDCBT-I intervention adapted to a 6-week treatment period. Participants receive six online CBT-I modules and two online face-to-face therapy sessions delivered by a CBT-I-certified psychologist. Step 2 incorporates the same evidence-based CBT-I techniques as the eSTANDCBT-I program. All participants receive Step 1. Only participants with persistent insomnia symptoms after the 4-week assessment proceed to Step 2. Participants also complete a daily sleep diary throughout the 10-week intervention.

Standard web-based Cognitive Behavioral Therapy for Insomnia: The eSTANDCBT-I intervention consists of a standard web-based Cognitive Behavioral Therapy for Insomnia (CBT-I) program delivered over a 10-week period. The program includes six online self-guided sessions and two online face-to-face therapy sessions with a CBT-I-certified psychologist. Participants receive: access to an online CBT-I platform containing weekly modules with educational videos, interactive exercises, and supporting materials; and two online face-to-face therapy sessions delivered by a CBT-I-certified psychologist. The intervention incorporates evidence-based CBT-I components commonly used in face-to-face clinical practice, including: sleep education and sleep hygiene; sleep restriction therapy and stimulus control; cognitive restructuring of maladaptive sleep-related thoughts and beliefs; stress management; relaxation training; and daily-life integration and relapse prevention. Participants are asked to complete a daily sleep diary throughout the 10-week intervention.

Control arm - Care as usual with sleep hygiene leaflet: Participants will receive an online sleep hygiene brochure and may seek additional or new sleep support from their usual healthcare providers if needed during the study. No study-specific sleep intervention will be provided, and the care received will be monitored as usual care. Participants will also complete a logbook and sleep diary throughout the study to enable comparison with the experimental groups. After all data collection has been completed, all intervention materials, including the online eSTANDCBT-I program, will be made available to them.

Study summary

The goal of this multicenter randomized clinical trial is to develop and evaluate a web-based stepped-care approach to Cognitive Behavioral Therapy for Insomnia (CBT-I), specifically tailored to adult cancer survivors experiencing insomnia. Participants will be randomly assigned to one of three study arms: stepped-care web-based CBT-I (eSTEPCBT-I), standardized web-based CBT-I (eSTANDCBT-I), or care as usual (CAU). The study aims to determine whether a stepped-care approach can improve access to effective insomnia treatment while maintaining clinical effectiveness and cost-effectiveness.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult cancer survivors (all cancer types), who are cancer-free and have completed primary cancer treatment (radiotherapy, chemotherapy, and surgery) ≥ 3 months prior. * Age ≥ 18 years * Sufficient proficiency in Dutch reading and comprehension. * Insomnia Severity Index (ISI) score ≥ 12 * Co-occurring sleep disorders permitted, provided they are adequately treated (e.g., obstructive sleep apnea managed with CPAP) * Concurrent use of (sleep) medication permitted. Exclusion Criteria: * Presence of active cancer or ongoing cancer treatment (except immunotherapy or hormonal therapy). * Severe psychiatric disorders (e.g., diagnosis of bipolar disorder or schizophrenia), or significant indication as identified via the MINI-screen, that would impede trial participation * Significant indication of cognitive impairment (score of 11 or more on the 6-CIT), rendering trial participation difficult. * Prior receipt of psychological treatment targeting insomnia (CBT-I) * Other untreated sleep disorders, as determined through a sleep interview and the SLAAP-50. * Engagement in shift work during the past 3 months or planned shift work within the upcoming 15 months * Current pregnancy or being a parent/primary caregiver of an infant aged ≤ 6 months

Primary outcome measure(s)

  • Insomnia Severity as assessed by the Insomnia Severity Index (ISI) — Baseline before the intervention (T0), within 4 weeks after the start of the intervention (T1), after 10 weeks of intervention (post intervention)(T2), and at 6 months post-intervention (T3) and 12 months post-intervention (T4).
    Insomnia severity is assessed using the Insomnia Severity Index (ISI), a validated 7-item questionnaire with a total score ranging from 0 to 28. Higher scores indicate greater insomnia severity (worse outcome).
  • Insomnia Remission Rate assesed by use of the Insomnia Severity Index (ISI) — Baseline before the intervention (T0), within 4 weeks after the start of the intervention (T1), after 10 weeks of intervention (post-intervention, T2), and at 6 months (T3) and 12 months (T4) post-intervention.
    Insomnia remission is defined as an ISI total score of 11 or lower (≤11). The remission rate is expressed as the percentage of participants achieving remission, with higher percentages indicating a better outcome.

Trial sites (1)

FacilityCityRegionStatus
Vrije Universiteit Brussel Brussels Belgium
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07876661 on ClinicalTrials.gov ↗ ← All trials in Belgium